Home > Gastroenterology > Surufatinib improves progression-free survival in advanced pancreatic neuroendocrine tumors

Surufatinib improves progression-free survival in advanced pancreatic neuroendocrine tumors


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
Lancet Oncology
Reuters Health - 09/10/2020 - Surufatinib improves progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (NETs), according to results from the phase-3 SANET-p study. "The surufatinib phase-1, phase-2, and SANET-p studies all demonstrated antitumor activity in heavily pretreated patients, including those failed on sunitinib and everolimus," Dr. Jianming Xu of The Fifth Medical Center, Chinese PLA General Hospital, in Beijing, told Reuters Health by email. "Surufatinib would provide clinically meaningful benefit for these patients with refractory diseases." Surufatinib is a small-molecule inhibitor that simultaneously targets tumor angiogenesis and immune invasion. In a separate phase-3 study, surufatinib significantly improved PFS in patients with NETs originating outside the pancreas. In the current study, Dr. Xu and colleagues from 21 hospitals across China assessed the safety and efficacy of surufatinib in a double-blind...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on